Rebuilding Trust in the Supplement Industry with AI

What we talked about.

Dr. Bill Clark, founder and CEO of Neutri Select, joins Sunny Ray to discuss rebuilding trust in the supplement industry through artificial intelligence. Clark traces his path from marine natural products chemistry, where he discovered new anti-cancer compounds, into three decades of supplement industry work spanning R&D, clinical research, certification, and entrepreneurship. He explains how his early involvement with NSF International's certification program addressed label claim and safety concerns, but left efficacy largely unresolved. Clark shares a defining moment when he refused to release incomplete clinical data to a brand seeking to hype results, choosing to shut down that business rather than compromise scientific integrity. He describes how generative AI finally made his long held vision executable, allowing Neutri Select to scale scientific evaluation of supplements in ways no individual researcher could. The conversation also touches on his upcoming book on conscious leadership and how philosophical discipline shapes his approach to fundraising, partnerships, and building a brand agnostic, evidence based intelligence platform for consumers.

A marine chemist turned serial entrepreneur explains how AI can finally prove which supplements actually work.

The questions, and the answers.

What is Neutri Select and why are you building it?

Neutri Select is my ninth venture, an intelligence platform built to solve the biggest unsolved problem in the supplement industry, which is helping people find evidence based products that actually work. The industry has addressed label claim and safety through regulation and certification, but efficacy is still mostly marketing rather than science. We are building a credibility engine to fix that.

What first pulled you toward chemistry and what did that early work teach you about discovery?

I went to UC Santa Cruz for marine biology, but an organic chemistry professor searching for new cancer drugs from the ocean hooked me. I worked in his lab, eventually discovering eight new compounds during my PhD, including one specific for C38 colon cancer. The bottom line is discovery begins with curiosity.

What opportunity did you see, and what frustrated you most, once you entered the supplement industry?

I was approached by a company called Pharmaprint doing serious research on botanicals. Before that I assumed supplements were a black box with no hard science behind them, and honestly that was largely true. That frustration became my mission, to bring real science into an industry that needed to become far more sophisticated.

What did your NSF International certification work teach you about quality standards versus consumer trust?

After the 1998 Centrum Herbals launch, NSF asked me to help start their third party certification program because we had raised the bar on testing and standards. That work focused on two pillars, label claim and safety, ensuring products actually contained what they said and were properly identified. Efficacy remained the missing third pillar.

Can you share the story about refusing to release early clinical data to a brand?

I ran a contract research organization doing clinical studies, and a large infomercial brand wanted early data before a study was complete so they could hype it in marketing. Our contract prohibited that, I refused, and they tried to sue me but had no case. After that I shut the business down rather than compromise my integrity.

When did the question of using technology to evaluate supplements become an actual company?

I first started thinking about applying emerging technology to this problem seriously back in 2018, but the tools were not advanced enough yet, so I parked the idea. About two and a half years ago, as generative AI emerged, I revisited it and began serious due diligence, which became Neutri Select.

What did AI finally make possible that wasn't practical before?

Scale. No scientist can read every clinical study and collate primary outcomes, secondary outcomes, and statistical analysis in their head. AI lets us evaluate that treasure trove of research in real time, identify gaps, and challenge simplified industry thinking, like the false assumption that more of a supplement always means more benefit.

How does your interest in conscious leadership affect practical founder decisions like fundraising and partnerships?

It comes from experience and is central to my upcoming second book, The Way of the Conscious Leader. First time founders often get desperate for capital, but you have to build real value first and let investment follow. That mindset lets you choose your partners and walk away from deals that do not serve the higher purpose of the venture.